Resource Summary Report

Generated by NIF on Sep 20, 2026

F-36P

RRID:CVCL_2037
Type: Cell Line

Proper Citation

RRID:CVCL_2037

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_2037

Proper Citation: RRID:CVCL_2037

Description: Cell line F-36P is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Acute erythroid leukemia

Defining Citation: PMID:1834251, PMID:16408098, PMID:22460905, PMID:23955599, PMID:25984343, PMID:26589293, PMID:27750403, PMID:30285677, PMID:30629668, PMID:30894373, PMID:31068700, PMID:31160637, PMID:31978347, PMID:36982453

Comments: Characteristics: CSF2 or IL3 dependent (PubMed=1834251)., Population: Japanese., Part of: LL-100 blood cancer cell line panel., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: F-36P

Synonyms: F36P

Cross References: CLO:CLO_0051549, AddexBio:C0003014/4881, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-7721, ArrayExpress:E-MTAB-7722, BioSample:SAMN03472228, BioSample:SAMN03473531, BioSample:SAMN10989568, cancercelllines:CVCL_2037, Cell_Model_Passport:SIDM01498, Cosmic:975247, Cosmic:1012066, Cosmic:1465955, Cosmic:2089665, Cosmic:2306204, DepMap:ACH-000487, DSMZ:ACC-543, DSMZCellDive:ACC-543, ECACC:99072808, FANTOM5_SSTAR:10837-111D9, GEO:GSM482505, GEO:GSM887010,

GEO:GSM888079, GEO:GSM1374478, GEO:GSM1446734, GEO:GSM2124120, IARC_TP53:28392, LiGeA:CCLE_670, Lonza:262, PharmacoDB:F36P_363_2019, Progenetix:CVCL_2037, RCB:RCB0775, TOKU-E:4108, Wikidata:Q54833036

ID: CVCL_2037

Record Creation Time: 20220427T215840+0000

Record Last Update: 20260920T002549+0000

Ratings and Alerts

No rating or validation information has been found for F-36P.

No alerts have been found for F-36P.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 2 mentions in open access literature.

Listed below are recent publications. The full list is available at NIF .

Kinloch AJ, et al. (2025) Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs. Cancers, 17(11).

Yabushita T, et al. (2023) Mitotic perturbation is a key mechanism of action of decitabine in myeloid tumor treatment. Cell reports, 42(9), 113098.